BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
20 März 2024 - 12:00PM
BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and
cell-derived therapeutics for the treatment of cardiovascular and
pulmonary diseases, today announced it will report its financial
results for the year ended December 31, 2023 and provide a
corporate update by conference call on Wednesday, March 27, 2024 at
4:30 PM ET. Following management’s formal remarks, there will be a
question-and-answer session.
Participants can register for the conference by navigating to
https://dpregister.com/sreg/10187416/fbec8cfa30. Please note that
registered participants will receive their dial-in number upon
registration. For those who have not registered, to listen to the
call by phone, interested parties within the U.S. should call
1-833-316-0559 and international callers should call
1-412-317-5730. All callers should dial in approximately 10 minutes
prior to the scheduled start time and ask to be joined into the
BioCardia call. The conference call will also be available through
a live webcast, which can be accessed through the following link:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=Ya3BT5pb.
A webcast replay of the call will be available approximately one
hour after the end of the call through June 26, 2024 at the above
links. A telephonic replay of the call will be available through
April 10, 2024 and may be accessed by calling 1-877-344-7529
(domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada)
by using access code 3499879.
About BioCardia®BioCardia,
Inc., headquartered in Sunnyvale, California, is developing
cellular and cell-derived therapeutics for the treatment of
cardiovascular and pulmonary disease. CardiAMP autologous and
CardiALLO allogeneic cell therapies are the Company’s
biotherapeutic platforms for the treatment of heart disease.
BioCardia also works with partners to provide its proprietary Helix
transendocardial biotherapeutic delivery system, as well as
technology and services for the development and commercialization
of partners’ therapeutic agents. For more information visit
www.biocardia.com.
MEDIA CONTACT:Miranda Peto, Marketing /
Investor Relations mpeto@biocardia.com (650) 226-0120
INVESTOR CONTACT:David McClung, Chief Financial
Officerinvestors@biocardia.com (650) 226-0120
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
Von Jun 2023 bis Jun 2024